Patent portfolios: maximise the value and minimise the cost

According to patent information company IFI Claims, 66% of what it said were the most prolific patenting companies also feature in the Financial Times’stop 500—compelling evidence that research and development (R&D) today creates tomorrow’s successes.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Final call: Who are the world’s best in-house counsel?

16 January 2026 A first-of-its-kind project by sister title WIPR aims to highlight the world’s leading in-house intellectual property counsel—and it needs your help.

Europe

Italian medtech startup beats larger US rival in UPC dispute

15 January 2026 Case between AorticLab and Emboline has implications for UPC playbook in terms of requesting security for costs, and conditional counterclaims.

Europe

Bayer secures key Denmark ruling as Xarelto faces expiry pressure

13 January 2026 As the drug moves deeper into its post-exclusivity phase, a Nordic decision highlights the value of secondary patents, presumption of validity, and interim relief when a drug's core patents expire.

More features

Skinny labels, big stakes: SCOTUS lines up the case of the year

$5.4bn medtech leader fails to bury a rival's patent

Final call: Who are the world’s best in-house counsel?

ITC to probe Oura Ring after Samsung retaliates, seeking import ban

Speciality pharma firm stumbles on bid to enforce Belbuca ruling

Italian medtech startup beats larger US rival in UPC dispute

Goodwin targets transatlantic patent work with London hire

Bayer secures key Denmark ruling as Xarelto faces expiry pressure

Patent portfolios: maximise the value and minimise the cost

More on this story

Editor's picks

Editor's picks

More features